Show simple item record

dc.contributor.authorZaidat, Osama O.
dc.contributor.authorBozorgchami, Hormozd
dc.contributor.authorRibó, Marc
dc.contributor.authorSaver, Jeffrey L.
dc.contributor.authorMattle, Heinrich P.
dc.contributor.authorChapot, René
dc.contributor.authorNarata, Ana Paula
dc.contributor.authorFrancois, Olivier
dc.contributor.authorJadhav, Ashutosh P.
dc.contributor.authorGrossberg, Jonathan A.
dc.contributor.authorRiedel, Christian H.
dc.contributor.authorTomasello, Alejandro
dc.contributor.authorClark, Wayne M.
dc.contributor.authorNordmeyer, Hannes
dc.contributor.authorLin, Eugene
dc.contributor.authorNogueira, Raul G.
dc.contributor.authorYoo, Albert J.
dc.contributor.authorJovin, Tudor G.
dc.contributor.authorSiddiqui, Adnan H.
dc.contributor.authorBernard, Thierry
dc.contributor.authorClaffey, Mairsíl
dc.contributor.authorAndersson, Tommy
dc.identifier.citationZaidat, Osama O. Bozorgchami, Hormozd; Ribó, Marc; Saver, Jeffrey L.; Mattle, Heinrich P.; Chapot, René; Narata, Ana Paula; Francois, Olivier; Jadhav, Ashutosh P.; Grossberg, Jonathan A.; Riedel, Christian H.; Tomasello, Alejandro; Clark, Wayne M.; Nordmeyer, Hannes; Lin, Eugene; Nogueira, Raul G.; Yoo, Albert J.; Jovin, Tudor G.; Siddiqui, Adnan H.; Bernard, Thierry; Claffey, Mairsíl; Andersson, Tommy (2018). Primary results of the multicenter arise ii study (analysis of revascularization in ischemic stroke with embotrap). Stroke 49 (5),
dc.description.abstractBackground and Purpose-EmboTrap is a novel stent retriever designed to achieve rapid and substantial flow restoration in acute ischemic stroke secondary to large-vessel occlusions. Here, we evaluated EmboTrap's safety and efficacy compared with established stent retrievers. Methods-ARISE II (Analysis of Revascularization in Ischemic Stroke With EmboTrap) was a single-arm, prospective, multicenter study, comparing the EmboTrap device to a composite performance goal criterion derived using a Bayesian meta-analysis from the pivotal SWIFT (Solitaire device) and TREVO 2 (Trevo device) trials. Patients at 11 US and 8 European sites were eligible for inclusion if they had large-vessel occlusions and moderate-to-severe neurological deficits within 8 hours of symptom onset. The primary efficacy end point was achievement of modified Thrombolysis in Cerebral Ischemia (mTICI) reperfusion scores of >= 2b within 3 EmboTrap passes as adjudicated by the core laboratory. The primary safety end point was a composite of symptomatic intracerebral hemorrhage and serious adverse device effects. Secondary end points included functional independence (modified Rankin Scale, 0-2) and all-cause mortality at 90 days. Results-Between October 2015 and February 2017, 227 patients were enrolled and treated with the EmboTrap device. The primary efficacy end point (mTICI >= 2b within 3 passes) was achieved in 80.2% (95% confidence interval, 74%-85% versus 56% performance goal criterion; P value, < 0.0001), and mTICI 2c/3 was 65%. After all interventions, mTICI 2c/3 was achieved in 76%, and mTICI >= 2b was 92.5%. The rate of first pass (mTICI >= 2b following a single pass) was 51.5%. The primary safety end point composite rate of symptomatic intracerebral hemorrhage or serious adverse device effects was 5.3%. Functional independence and all-cause mortality at 90 days were 67% and 9%, respectively. Conclusions-The EmboTrap stent-retriever mechanical thrombectomy device demonstrated high rates of substantial reperfusion and functional independence in patients with acute ischemic stroke secondary to large-vessel occlusions.
dc.publisherOvid Technologies (Wolters Kluwer Health)
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Ireland
dc.subjectindividual patient data
dc.subjectendovascular thrombectomy
dc.titlePrimary results of the multicenter arise ii study (analysis of revascularization in ischemic stroke with embotrap)

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Ireland
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Ireland